We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Aml4.8
Amla Research
Mostly mechanism / observational
5 peer-reviewed studies
Our research database did not respond in time, so this list covers only our curated studies. It refreshes automatically.
What the evidence says
Mostly mechanism / observational
Most Amla studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from medium-quality meta-analyses and randomised trials published 2019–2025 with a typical study size of 98 participants.
Based on 5 studies · 1 meta-analysis · 3 RCTs · 347 total participants
Confidence
Moderate confidence
By outcome
Glucose & metabolicSignificant fasting-glucose reduction in pooled RCT data, though trials are short and small · 4-12 weeks · Improved lipid ratios, lowered CRP, and reduced oxidative-stress markers in metabolic-syndrome subjects · 8-12 weeks
Mostly mechanism / observational3 studies
Heart & blood pressureModest reductions in total cholesterol, LDL, and triglycerides; improved endothelial function in several small RCTs · 8-12 weeks
Too few graded studies1 study
Active research area
3 studies in the last 5 years · Latest meta-analysis: 2023
20192025
1RCTCited 9×n=150 · medium study2021
In plain English: The treatment with Phyllanthus emblica failed to produce any additional reduction in systolic and/or diastolic blood pressure levels and did not exhibit improvement in oxidant status, antioxidant capacity, lipid profile, HbA1C, arterial stiffness parameters, or hs-CRP levels.
Shanmugarajan D, Girish C, Harivenkatesh N, et al. · Phytother Res (2021)
No additional reduction in systolic or diastolic blood pressure versus placebo
No improvement in lipid profile, oxidant/antioxidant status, HbA1c, arterial stiffness, or hs-CRP
Larger (150-patient), rigorous double-blind RCT — a clear negative result that tempers the positive trials
In plain English: Following Amla supplementation, pooled results showed a significant reduction in CRP (p = 0.002), fasting blood glucose (FBG) (p < 0.001), low-density lipoprotein cholesterol (LDL-c) (p < 0.001), total cholesterol (TC) (p < 0.001), and serum triglyceride (TG) (p < 0.001) concentrations as well as an increase in high-density lipoprotein cholesterol (HDL-c) (p < 0.001).
Setayesh L, Haghighat N, Rasaei N, et al. · Diabetes Metab Syndr (2023)
Significant reduction in total cholesterol, LDL-c, and triglycerides (all p < 0.001)
Significant reduction in fasting blood glucose (p < 0.001) and CRP (p = 0.002)
In plain English: In 12 weeks, the major lipids such as total cholesterol (TC) (p = 0.0003), triglyceride (TG) (p = 0.0003), low density lipoprotein cholesterol (LDL-C) (p = 0.0064) and very low density lipoprotein cholesterol (VLDL-C) (p = 0.0001) were significantly lower in amla group as compared to placebo group.
Upadya H, Prabhu S, Prasad A, et al. · BMC Complement Altern Med (2019)
Significant reductions in total cholesterol (p = 0.0003), triglycerides (p = 0.0003), LDL-C (p = 0.0064), and VLDL-C (p = 0.0001)
39% reduction in atherogenic index of plasma (p = 0.0177)
Cholesterol reduction achieved without depleting CoQ10, unlike statins
In plain English: P.emblica aqueous extract significantly improved endothelial function, oxidative stress, systemic inflammation and lipid profile at both dosages tested, but especially at 500 mg twice daily.
Usharani P, Merugu PL, Nutalapati C. · BMC Complement Altern Med (2019)
Significant improvement in reflection index (endothelial function) at 8 and 12 weeks (p < 0.001)
Improved nitric oxide, glutathione, and malondialdehyde; reduced hsCRP (up to -53.77%)
Reduced total cholesterol, LDL, and triglycerides; raised HDL